Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients

Bibliography

• UNAIDS. The Gap Report. 2014. Available from: http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf [Last accessed 1 April 2015]
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2015. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [Last accessed 18 April 2015]
   Google Scholar
• Oxlade O, Piatek A, Vincent C, Menzies D. Modeling the impact of tuberculosis interventions on epidemiologic outcomes and health system costs. BMC Public Health 2015;15(1):141
   PubMedGoogle Scholar
• Rowley M. The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection. Prog Med Chem 2008;46:1–28
   PubMedGoogle Scholar
• Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006;43(5):509–15
   PubMed Web of Science ®Google Scholar
• Brainard DM, Friedman EJ, Jin B, et al. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmacol 2011;51(3):422–7
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Gervasoni C, Meraviglia P, et al. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother 2012;67(2):460–4
   PubMed Web of Science ®Google Scholar
• Siccardi M, D’Avolio A, Rodriguez-Novoa S. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. Ther Drug Monit 2012;34(2):232–5
   PubMed Web of Science ®Google Scholar
• Moss DM, Siccardi M, Back DJ, Owen A. Predicting intestinal absorption of raltegravir using a population-based ADME simulation. J Antimicrob Chemother 2013;68(7):1627–34
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Baldelli S, Cerea M, et al. Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing. Antimicrob Agents Chemother 2012;56(12):6132–6
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Cossu MV, Fucile S, et al. Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study. Ther Drug Monit 2015;37(1):119–25
   PubMed Web of Science ®Google Scholar
• Spinner CD, Wille F, Schwerdtfeger C, et al. Pharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data. AIDS Res Ther 2015;12(1):1
   PubMedGoogle Scholar
• Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007;35(9):1657–63
   PubMed Web of Science ®Google Scholar
• Wenning LA, Petry AS, Kost JT, et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther 2009;85(6):623–7
   PubMed Web of Science ®Google Scholar
• Rizk ML, Hang Y, Luo WL, et al. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother 2012;56(6):3101–6
   PubMed Web of Science ®Google Scholar
• Hernández-Novoa B, Moreno A, Pérez-Elías MJ, et al. Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C). J Antimicrob Chemother 2014;69(2):471–5
   PubMed Web of Science ®Google Scholar
• Watts DH, Stek A, Best BM, et al. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr 2014;67(4):375–81
   PubMed Web of Science ®Google Scholar
• Calcagno A, Cusato J, Simiele M, et al. High interpatient variability of raltegravir cerebrospinal fluid concentrations in HIV-positive patients: a pharmacogenetic analysis. J Antimicrob Chemother 2014;69(1):241–5
   PubMed Web of Science ®Google Scholar
• Croteau D, Letendre S, Best BM, et al. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother 2010;54(12):5156–60
   PubMed Web of Science ®Google Scholar
• Calcagno A, Simiele M, Alberione MC, et al. Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control. Clin Infect Dis 2015;60(2):311–17
   PubMed Web of Science ®Google Scholar
• Antoniou T, Loutfy MR, Brunetta J, et al. Pharmacokinetics of raltegravir in the semen of HIV-infected men. Antivir Ther 2014;19(6):607–11
   PubMed Web of Science ®Google Scholar
• Clavel C, Peytavin G, Tubiana R, et al. Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study). Antimicrob Agents Chemother 2011;55(6):3018–21
   PubMed Web of Science ®Google Scholar
• Clarke DF, Acosta EP, Rizk ML, et al. Raltegravir pharmacokinetics in neonates following maternal dosing. J Acquir Immune Defic Syndr 2014;67(3):310–15
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Gervasoni C, Cozzi V, et al. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients. Pharmacol Res 2012;65(2):198–203
   PubMed Web of Science ®Google Scholar
• Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2008;52(9):3253–8
   PubMed Web of Science ®Google Scholar
• Calcagno A, Gonzalez de Requena D, Simiele M, et al. Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function. Antimicrob Agents Chemother 2013;57(4):1840–3
   PubMed Web of Science ®Google Scholar
• Moss DM, Kwan WS, Liptrott NJ, et al. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2011;55(2):879–87
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, De Castro N, Arnold V, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis 2014;14(6):459–67
   PubMed Web of Science ®Google Scholar
• Jansen A, Colbers EP, van der Ven AJ, et al. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients. HIV Med 2013;14(7):449–52
   PubMed Web of Science ®Google Scholar
• Calcagno A, Tettoni MC, Simiele M, et al. Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. J Antimicrob Chemother 2013;68(2):482–4
   PubMed Web of Science ®Google Scholar
• Khatri A, Wang T, Wang H, et al. Drug-drug interactions of the direct acting antiviral regimen of ABT 450/r, ombitasvir and dasabuvir with emtricitabine + tenofovir, raltegravir, rilpivirine and efavirenz [Abstract V-483]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 5-9September 2014; Washington, DC
   Google Scholar
• Madeddu G, Menzaghi B, Ricci E, et al. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. AIDS 2012;26(18):2412–15
   PubMed Web of Science ®Google Scholar
• Moss DM, Siccardi M, Murphy M, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother 2012;56(6):3020–6
   PubMed Web of Science ®Google Scholar
• Thierry S, Munir S, Thierry E, et al. Integrase inhibitor reversal dynamics indicate unintegrated HIV-1 DNA initiate de novo integration. Retrovirology 2015;12:24
   PubMed Web of Science ®Google Scholar
• Hazuda D, Iwamoto M, Wenning L. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol 2009;49:377–94
   PubMed Web of Science ®Google Scholar
• Hightower KE, Wang R, Deanda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011;55(10):4552–9
   PubMed Web of Science ®Google Scholar
• Nóbrega I, Travassos AG, Haguihara T, et al. Short communication: Use of raltegravir in late-presenting HIV-infected pregnant women. AIDS Res Hum Retroviruses 2013;29(11):1451–4
   PubMed Web of Science ®Google Scholar
• Buzón MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010;16(4):460–5
   PubMed Web of Science ®Google Scholar
• Tunjungputri RN, Van Der Ven AJ, Schonsberg A, et al. Reduced platelet hyperreactivity and platelet-monocyte aggregation in HIV-infected individuals receiving a raltegravir-based regimen. AIDS 2014;28(14):2091–6
   PubMed Web of Science ®Google Scholar
• Fransen S, Gupta S, Frantzell A, et al. Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo. J Virol 2012;86(13):7249–55
   PubMed Web of Science ®Google Scholar
• Garrido C, de Mendoza C, Alvarez E, et al. Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations. AIDS Res Hum Retroviruses 2012;28(2):156–64
   PubMed Web of Science ®Google Scholar
• Hurt CB, Sebastian J, Hicks CB, Eron JJ. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 2014;58(3):423–31
   PubMed Web of Science ®Google Scholar
• Grobler JA, Hazuda DJ. Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences. Curr Opin Virol 2014;8:98–103
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr 2013;63(1):77–85
   PubMed Web of Science ®Google Scholar
• Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 2014;161(7):461–71
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381(9868):735–43
   PubMed Web of Science ®Google Scholar
• Reynes J, Lawal A, Pulido F, et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results. HIV Clin Trials 2011;12(5):255–67
   PubMed Web of Science ®Google Scholar
• Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014;384(9958):1942–51
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359(4):339–54
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013;382(9893):700–8
   PubMed Web of Science ®Google Scholar
• Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012;12(1):27–35
   PubMed Web of Science ®Google Scholar
• Boyd MA, Kumarasamy N, Moore CL, et al. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet 2013;381(9883):2091–9
   PubMed Web of Science ®Google Scholar
• Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375(9712):396–407
   PubMed Web of Science ®Google Scholar
• Vispo E, Barreiro P, Maida I, et al. Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. HIV Clin Trials 2010;11(4):197–204
   PubMed Web of Science ®Google Scholar
• Martínez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010;24(11):1697–707
   PubMed Web of Science ®Google Scholar
• Bloch M, Tong WW, Hoy J, et al. Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks. HIV Med 2014;15(6):373–80
   PubMed Web of Science ®Google Scholar
• Cordery DV, Hesse K, Amin J, Cooper DA. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antivir Ther 2010;15(7):1035–8
   PubMed Web of Science ®Google Scholar
• Gantner P, Koeppel C, Partisani M, et al. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study. Scand J Infect Dis 2014;46(12):838–45
   PubMed Web of Science ®Google Scholar
• Monteiro P, Perez I, Laguno M, et al. Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study. J Antimicrob Chemother 2014;69(3):742–8
   PubMed Web of Science ®Google Scholar
• Reliquet V, Chirouze C, Allavena C, et al. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients. Antivir Ther 2014;19(1):117–23
   PubMed Web of Science ®Google Scholar
• Nozza S, Bigoloni A, Calcagno A, et al. Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. J Antimicrob Chemother 2014;69(5):1436–9
   PubMed Web of Science ®Google Scholar
• Katlama C, Assoumou L, Valantin MA, et al. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. J Antimicrob Chemother 2014;69(6):1648–52
   PubMed Web of Science ®Google Scholar
• Harris M, Larsen G, Montaner JS. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 2008;22(14):1890–2
   PubMed Web of Science ®Google Scholar
• Madeddu G, De Socio GV, Ricci E, et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. Int J Antimicrob Agents 2015;45(3):289–94
   PubMed Web of Science ®Google Scholar
• Perry ME, Almaani N, Desai N, et al. Raltegravir-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome - implications for clinical practice and patient safety. Int J STD AIDS 2013;24(8):639–42
   PubMed Web of Science ®Google Scholar